The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders

Prashant Kapoor, James A. Martenson

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Plasma cell malignancies are radioresponsive. Radiation is used as primary or adjunctive therapy of plasma cell disorders (PCDs). Palliation of symptoms is the commonest indication for radiation to the skeletal and soft tissue myelomatous lesions. Other indications include pretransplant conditioning, myeloma-related cord compression, or impending pathological fractures. Radiation is also utilized in the management of solitary osseous and extramedullary plasmacytomas, POEMS syndrome with a limited number of lesions, localized AL amyloidosis and rarely, Waldenström’s macroglobulinemia. Anecdotal reports outlining successful use of radiation with novel anti-myeloma agents exist. This chapter focuses on conventional radiation and chemo-radiation-based management strategies in PCDs.

Original languageEnglish (US)
Title of host publicationMultiple Myeloma: Diagnosis and Treatment
PublisherSpringer New York
Pages233-244
Number of pages12
ISBN (Print)9781461485209, 9781461485193
DOIs
StatePublished - Jan 1 2014

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'The role of radiation therapy in the treatment of multiple myeloma, plasmacytoma, and other plasma cell disorders'. Together they form a unique fingerprint.

Cite this